127 related articles for article (PubMed ID: 33194740)
1. Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts.
Qiao P; Ayat NR; Vaidya A; Gao S; Sun W; Chou S; Han Z; Gilmore H; Winter JM; Lu ZR
Front Oncol; 2020; 10():586727. PubMed ID: 33194740
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.
Vaidya A; Ayat N; Buford M; Wang H; Shankardass A; Zhao Y; Gilmore H; Wang Z; Lu ZR
Theranostics; 2020; 10(24):11127-11143. PubMed ID: 33042274
[TBL] [Abstract][Full Text] [Related]
3. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis.
Qiao PL; Gargesha M; Liu Y; Laney VEA; Hall RC; Vaidya AM; Gilmore H; Gawelek K; Scott BB; Roy D; Wilson DL; Lu ZR
Magn Reson Imaging; 2022 Feb; 86():37-45. PubMed ID: 34801672
[TBL] [Abstract][Full Text] [Related]
5. Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses.
Ayat NR; Vaidya A; Yeung GA; Buford MN; Hall RC; Qiao PL; Yu X; Lu ZR
Front Oncol; 2019; 9():1351. PubMed ID: 31850230
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.
Han Z; Cheng H; Parvani JG; Zhou Z; Lu ZR
Magn Reson Med; 2018 Jun; 79(6):3135-3143. PubMed ID: 29082597
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.
Hall RC; Ayat NR; Qiao PL; Vaidya AM; Ma D; Aminoshariae A; Stojanov I; Lu ZR
Mol Imaging Biol; 2020 Dec; 22(6):1532-1542. PubMed ID: 32789648
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging.
Schilb AL; Ayat NR; Vaidya AM; Hertz LM; Hall RC; Scheidt JH; Sun D; Sun Z; Gopalakrishnan R; Lu ZR
Pharm Res; 2021 Aug; 38(8):1405-1418. PubMed ID: 34389916
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and assessment of ZD2-(
Gao S; Qin J; Sergeeva O; Sergeev M; Qiao P; Roelle S; Avril N; Lee Z; Li Y; Lu Z
Am J Nucl Med Mol Imaging; 2019; 9(5):216-229. PubMed ID: 31772820
[TBL] [Abstract][Full Text] [Related]
10. Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.
Han Z; Li Y; Roelle S; Zhou Z; Liu Y; Sabatelle R; DeSanto A; Yu X; Zhu H; Magi-Galluzzi C; Lu ZR
Bioconjug Chem; 2017 Apr; 28(4):1031-1040. PubMed ID: 28201871
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Dual-Targeted ECO/siRNA Nanoparticles against an Oncogenic lncRNA for Triple Negative Breast Cancer Therapy with Magnetic Resonance Molecular Imaging.
Nicolescu C; Schilb A; Kim J; Sun D; Hall R; Gao S; Gilmore H; Schiemann WP; Lu ZR
Chem Biomed Imaging; 2023 Aug; 1(5):461-470. PubMed ID: 37655165
[TBL] [Abstract][Full Text] [Related]
13. EDB Fibronectin Specific Peptide for Prostate Cancer Targeting.
Han Z; Zhou Z; Shi X; Wang J; Wu X; Sun D; Chen Y; Zhu H; Magi-Galluzzi C; Lu ZR
Bioconjug Chem; 2015 May; 26(5):830-8. PubMed ID: 25848940
[TBL] [Abstract][Full Text] [Related]
14. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent.
Zhang W; Liang X; Zhang X; Tong W; Shi G; Guo H; Jin Z; Tian J; Du Y; Xue H
Eur J Nucl Med Mol Imaging; 2024 Feb; ():. PubMed ID: 38372766
[TBL] [Abstract][Full Text] [Related]
15. EDB Fibronectin-Specific SPECT Probe
Ye XX; Zhao YY; Wang Q; Xiao W; Zhao J; Peng YJ; Cao DH; Lin WJ; Si-Tu MY; Li MZ; Zhang X; Zhang WG; Xia YF; Yang X; Feng GK; Zeng MS
ACS Omega; 2017 Jun; 2(6):2459-2468. PubMed ID: 30023665
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218.
Li Y; Gao S; Jiang H; Ayat N; Laney V; Nicolescu C; Sun W; Tweedle MF; Lu ZR
Invest Radiol; 2022 Oct; 57(10):639-654. PubMed ID: 35703463
[TBL] [Abstract][Full Text] [Related]
17. Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI.
Ayat NR; Qin JC; Cheng H; Roelle S; Gao S; Li Y; Lu ZR
ACS Med Chem Lett; 2018 Jul; 9(7):730-735. PubMed ID: 30034609
[TBL] [Abstract][Full Text] [Related]
18. EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer.
Li R; He H; Li X; Zheng X; Li Z; Zhang H; Ye J; Zhang W; Yu C; Feng G; Fan W
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2100-2113. PubMed ID: 36807768
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery.
Yu M; Ortega CA; Si K; Molinaro R; Schoen FJ; Leitao RFC; Xu X; Mahmoudi M; Ahn S; Liu J; Saw PE; Lee IH; Brayner MMB; Lotfi A; Shi J; Libby P; Jon S; Farokhzad OC
Theranostics; 2018; 8(21):6008-6024. PubMed ID: 30613278
[TBL] [Abstract][Full Text] [Related]
20. Preparation and Evaluation of ZD2 Peptide
Han Z; Sergeeva O; Roelle S; Cheng H; Gao S; Li Y; Lee Z; Lu ZR
ACS Omega; 2019 Jan; 4(1):1185-1190. PubMed ID: 30729224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
